← Browse by Condition
Medical Condition

jak2 v617f

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 3

ClinicalMetric tracks all active clinical trials for jak2 v617f sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.

  • Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
  • Phase 1–4 studies from early safety trials to post-marketing surveillance
  • NIH, pharmaceutical sponsor, and academic medical center studies worldwide
  • AI-powered plain-language summary available for every trial listing
Trial Phases
Phase 3
1
Top Sponsors
University Hospital, Brest 1 trial
NCT05198960 Phase 3
Recruiting

AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms

Enrollment
1,308 pts
Location
France
Sponsor
University Hospital, Brest
View Trial →